Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

738 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and Efficacy of Low-dose Nanoparticle Albumin-bound Paclitaxel for HER2-negative Metastatic Breast Cancer.
Takashima T, Kawajiri H, Nishimori T, Tei S, Nishimura S, Yamagata S, Tokunaga S, Mizuyama Y, Sunami T, Tezuka K, Ikeda K, Ogawa Y, Kashiwagi S, Noda S, Onoda N, Ishikawa T, Kudoh S, Takada M, Hirakawa K, Ohira M. Takashima T, et al. Among authors: yamagata s. Anticancer Res. 2018 Jan;38(1):379-383. doi: 10.21873/anticanres.12233. Anticancer Res. 2018. PMID: 29277798
A phase II, multicenter, single-arm trial of eribulin as first-line chemotherapy for HER2-negative locally advanced or metastatic breast cancer.
Takashima T, Tokunaga S, Tei S, Nishimura S, Kawajiri H, Kashiwagi S, Yamagata S, Noda S, Nishimori T, Mizuyama Y, Sunami T, Tezuka K, Ikeda K, Ogawa Y, Onoda N, Ishikawa T, Kudoh S, Takada M, Hirakawa K. Takashima T, et al. Among authors: yamagata s. Springerplus. 2016 Feb 24;5:164. doi: 10.1186/s40064-016-1833-1. eCollection 2016. Springerplus. 2016. PMID: 27026861 Free PMC article.
Phase I study of nanoparticle albumin-bound paclitaxel, carboplatin and trastuzumab in women with human epidermal growth factor receptor 2-overexpressing breast cancer.
Tezuka K, Takashima T, Kashiwagi S, Kawajiri H, Tokunaga S, Tei S, Nishimura S, Yamagata S, Noda S, Nishimori T, Mizuyama Y, Sunami T, Ikeda K, Ogawa Y, Onoda N, Ishikawa T, Kudoh S, Takada M, Hirakawa K. Tezuka K, et al. Among authors: yamagata s. Mol Clin Oncol. 2017 Apr;6(4):534-538. doi: 10.3892/mco.2017.1176. Epub 2017 Feb 24. Mol Clin Oncol. 2017. PMID: 28413662 Free PMC article.
Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Trastuzumab Followed by 5-Fluorouracil/Epirubicin/Cyclophosphamide for HER2-positive Operable Breast Cancer: A Multicenter Phase II Trial.
Tokunaga S, Takashima T, Kashiwagi S, Noda S, Kawajiri H, Tokumoto M, Nishimura S, Nishimori T, Ikeda K, Ogawa Y, Mizuyama Y, Sunami T, Tezuka K, Yamagata S, Ishikawa T, Kudoh S, Takada M, Hirakawa K, Ohira M. Tokunaga S, et al. Among authors: yamagata s. Anticancer Res. 2019 Apr;39(4):2053-2059. doi: 10.21873/anticanres.13316. Anticancer Res. 2019. PMID: 30952749 Clinical Trial.
An Exploratory Phase II Study of Eribulin Re-challenge After Short Term Therapy of 5-Fluorouracil for HER2 Negative, Advanced or Recurrent Breast Cancer.
Takashima T, Nishimura S, Kawajiri H, Mizuyama Y, Nishimori T, Yamagata S, Tokunaga S, Tezuka K, Tei S, Sunami T, Ikeda K, Ogawa Y, Kashiwagi S, Noda S, Onoda N, Ishikawa T, Kudoh S, Takada M, Hirakawa K, Ohira M. Takashima T, et al. Among authors: yamagata s. Anticancer Res. 2021 Oct;41(10):5007-5014. doi: 10.21873/anticanres.15315. Anticancer Res. 2021. PMID: 34593449 Clinical Trial.
[A Case of Cecal Cancer with Multiple Cutaneous Metastases].
Komoto M, Tanaka R, Kametani N, Kato Y, Yamagata S, Nakazawa K, Kanehara I, Ako E, Yamada N, Nishimura S, Fujita S, Taenaka N. Komoto M, et al. Among authors: yamagata s. Gan To Kagaku Ryoho. 2015 Nov;42(12):2125-7. Gan To Kagaku Ryoho. 2015. PMID: 26805285 Japanese.
738 results